Results of a Phase 2, Randomized, Double-Blind Study of Sorafenib Versus Placebo in Combination with Intensive Chemotherapy in Previously Untreated Patients with FLT3-ITD Acute Myeloid Leukemia (ALLG AMLM16)
暂无分享，去创建一个
P. Marlton | A. Roberts | A. Wei | M. Levis | C. Tiley | A. Enjeti | S. Ting | A. Schwarer | T. Rawling | K. Morris | G. Kennedy | I. Tiong | U. Hahn | M. Murray | A. Grigg | J. D’Rozario | A. Bajel | N. Anstee | M. Latimer | H. Iland | D. Hiwase | S. He | J. Leadbetter | M. Wall | E. Verner | I. Bilmon | S. Yuen | G. Cull | J. Taper | D. M. Ong | S. Loo | N. Murphy | U. Nguyen | Sundra Ravanathan